DK0650965T3 - Asymmetrisk syntese af (S)-(+)-N,N-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamin, et mellemprodukt ved fremstilling - Google Patents

Asymmetrisk syntese af (S)-(+)-N,N-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamin, et mellemprodukt ved fremstilling

Info

Publication number
DK0650965T3
DK0650965T3 DK94307394T DK94307394T DK0650965T3 DK 0650965 T3 DK0650965 T3 DK 0650965T3 DK 94307394 T DK94307394 T DK 94307394T DK 94307394 T DK94307394 T DK 94307394T DK 0650965 T3 DK0650965 T3 DK 0650965T3
Authority
DK
Denmark
Prior art keywords
propanamine
thienyl
dimethyl
equiv
stirring
Prior art date
Application number
DK94307394T
Other languages
English (en)
Inventor
Richard Alan Berglund
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0650965T3 publication Critical patent/DK0650965T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94307394T 1993-10-12 1994-10-07 Asymmetrisk syntese af (S)-(+)-N,N-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamin, et mellemprodukt ved fremstilling DK0650965T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/135,032 US5362886A (en) 1993-10-12 1993-10-12 Asymmetric synthesis

Publications (1)

Publication Number Publication Date
DK0650965T3 true DK0650965T3 (da) 2001-02-26

Family

ID=22466186

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94307394T DK0650965T3 (da) 1993-10-12 1994-10-07 Asymmetrisk syntese af (S)-(+)-N,N-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamin, et mellemprodukt ved fremstilling

Country Status (30)

Country Link
US (2) US5362886A (da)
EP (1) EP0650965B1 (da)
JP (1) JP3644986B2 (da)
KR (1) KR100334585B1 (da)
CN (1) CN1067681C (da)
AT (1) ATE199084T1 (da)
AU (1) AU685494B2 (da)
BR (1) BR9404045A (da)
CA (1) CA2133899C (da)
CO (1) CO4290349A1 (da)
CZ (1) CZ286122B6 (da)
DE (1) DE69426663T2 (da)
DK (1) DK0650965T3 (da)
ES (1) ES2153850T3 (da)
FI (1) FI944773A (da)
GR (1) GR3035715T3 (da)
HU (2) HU220673B1 (da)
IL (1) IL111188A (da)
MY (1) MY112254A (da)
NO (1) NO301758B1 (da)
NZ (1) NZ264633A (da)
PE (1) PE18595A1 (da)
PH (1) PH31595A (da)
PL (1) PL179600B1 (da)
PT (1) PT650965E (da)
RU (1) RU2127269C1 (da)
SI (1) SI0650965T1 (da)
TW (1) TW381090B (da)
YU (1) YU49027B (da)
ZA (1) ZA947839B (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6199021B1 (en) 1997-10-15 2001-03-06 Cc Kinetics, Inc. Method and apparatus for measuring power output of one powering a chain driven vehicle
WO2000061540A1 (en) * 1999-04-09 2000-10-19 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP2005053781A (ja) * 2001-08-27 2005-03-03 Nagase & Co Ltd 光学活性な３−（ｎ−メチルアミノ）−１−（２−チエニル）−プロパン−１−オールの製造方法
WO2003062219A1 (en) * 2002-01-24 2003-07-31 Eli Lilly And Company Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
AU2003221028A1 (en) * 2002-03-19 2003-09-29 Mitsubishi Chemical Corporation 3-hydroxy-3-(2-thienyl)propionamide compound, process for producing the same, and process for producing 3-amino-1-(2-thienyl)-1-propanol compound therefrom
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
DE10212301A1 (de) 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen
WO2003097632A1 (fr) * 2002-05-20 2003-11-27 Mitsubishi Rayon Co., Ltd. Derives de propanolamine, procede de preparation de 3-n-methylamino-1-(2-thienyl)-1-propanols et procede de preparation de derives de propanolamine
WO2004005239A1 (en) * 2002-07-09 2004-01-15 Lonza Ag PROCESS FOR THE PREPARATION OF N-MONOSUBSTITUTED β-AMINO ALCOHOLS
FR2841899A1 (fr) * 2002-07-05 2004-01-09 Ppg Sipsy Procede de resolution asymetrique d'un racemique faisant intervenir l'acide diprogulique et utilisation dudit acide comme agent de resolution asymetrique
DK1852415T3 (da) * 2002-07-09 2010-01-25 Lonza Ag Fremgangsmåde til fremstilling af N-monosubstituerede beta-aminoalkoholer
WO2004005307A1 (en) * 2002-07-09 2004-01-15 Lonza Ag Process for the preparation of optically active 3-n-methylamino-1-(2-thienyl)-1-propanol
DE10235206A1 (de) * 2002-08-01 2004-02-19 Basf Ag Verfahren zur Herstellung von (S)-3-Methylmino-1-(thien-2-yl)propan-1-ol
EP1541569B1 (en) * 2002-08-06 2010-05-12 Sumitomo Seika Chemicals Co., Ltd. Process for producing n-monoalkyl-3-hydroxy-3-(2-thienyl)propanamine and intermediate
DE10237246B3 (de) * 2002-08-14 2004-01-22 Consortium für elektrochemische Industrie GmbH (S)-3-Methylamino-1-(2-thienyl)-1-propanol-(-)-2,3,4,6-Di-O-isopropyliden-2-keto-L-gulonsäuresalz, Verfahren zu dessen Herstellung, dessen Verwendung sowie ein Verfahren zur Enantiomerenanreicherung von (S)-3-Methylamino-1-(2-thienyl)-1-propanol
GB0221438D0 (en) * 2002-09-16 2002-10-23 Avecia Ltd Processes and compounds
AU2003276066A1 (en) * 2002-10-07 2004-04-23 Lonza Ag Processes and intermediates for the preparation of optically active 3-amino-1-(2-thienyl)-1-propanol derivatives
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
DE10302595A1 (de) * 2003-01-22 2004-07-29 Basf Ag 3-Methylamino-1-(2-thienyl)-1-proganon, seine Herstellung und Verwendung
AU2003263585A1 (en) * 2003-08-25 2005-03-10 Hetero Drugs Limited Amorphous duloxetine hydrochloride
DE10345772A1 (de) * 2003-10-01 2005-04-21 Basf Ag Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol
DE102004004719A1 (de) * 2004-01-29 2005-08-18 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
BRPI0506796A (pt) 2004-02-19 2007-05-22 Lonza Ag processo para a preparação de 1-substituìdos-3-aminoálcoois enantiomericamentente puros
US20050197503A1 (en) * 2004-03-05 2005-09-08 Boehringer Ingelheim International Gmbh Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines
CN1300137C (zh) * 2004-03-31 2007-02-14 上海医药工业研究院 (s)－(+)－n,n－二甲基－3－(1－萘氧基)－3－(2－噻吩基)丙胺的制备方法
DE102004022686A1 (de) 2004-05-05 2005-11-24 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
CZ297555B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
WO2006081515A2 (en) * 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride polymorphs
MX2007010931A (es) * 2005-03-08 2007-10-16 Teva Pharma Formas cristalinas de (s)-(+)-n,n-dimetil-3-(1-naftaleniloxi)-3-(2 -tienil)propanamina oxalato y la preparacion ellas.
EP1874754A1 (en) * 2005-03-14 2008-01-09 Teva Pharmaceutical Industries Ltd Pure duloxetine hydrochloride
WO2006126213A1 (en) * 2005-05-24 2006-11-30 Matrix Laboratories Ltd An improved process for the preparation of duloxetine
CN100364986C (zh) * 2005-07-14 2008-01-30 上海艾力斯医药科技有限公司 S－(+)－n,n－二甲基－3－(1－萘基氧基)－3－(2－噻吩基)丙胺的制备方法
JP5361187B2 (ja) 2005-08-19 2013-12-04 住友精化株式会社 （ｅ）−ｎ−モノアルキル−３−オキソ−３−（２−チエニル）プロペンアミンおよびその製造方法、ならびに（ｅ，ｚ）−ｎ−モノアルキル−３−オキソ−３−（２−チエニル）プロペンアミンの製造方法
US7842717B2 (en) * 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
CN1304360C (zh) * 2005-12-12 2007-03-14 天津大学 N,n－二甲基－3－羟基－3－芳基丙胺的制备方法
CA2634007A1 (en) 2005-12-12 2007-08-30 Medichem S.A. Improved synthesis and preparations of duloxetine salts
DE102005062661A1 (de) * 2005-12-23 2007-08-16 Basf Ag Verfahren zur Herstellung von optisch aktivem (1S)-3-Chlor-(-thien-2-yl)-propan-1-ol
DE102005062662A1 (de) 2005-12-23 2007-06-28 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
CZ299270B6 (cs) * 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
WO2007077580A2 (en) * 2006-01-06 2007-07-12 Msn Laboratories Limited Improved process for pure duloxetine hydrochloride
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
MX2007011727A (es) * 2006-01-23 2007-11-15 Teva Pharma Dnt-succinato y metodos de preparacion de el.
MX2007011611A (es) * 2006-01-23 2007-10-18 Teva Pharma Fumarato de dnt y metodos de preparacion de ellos.
EP1856088A1 (en) * 2006-01-23 2007-11-21 Teva Pharmaceutical Industries Ltd Dnt-benzenesulfonate and methods of preparation thereof
EP1976845A2 (en) * 2006-02-13 2008-10-08 Teva Pharmaceutical Industries Ltd A process for the preparation of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a duloxetine intermediate
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
US7560573B2 (en) * 2006-02-21 2009-07-14 Teva Pharmaceutical Industries Ltd Process for the preparation of (S)-(-)-N,N-dimethyl-3-(2-thienyl)-3-hydroxypropananine, a duloxetine intermediate
EP1826204A1 (en) 2006-02-28 2007-08-29 Laboratorios Del Dr. Esteve, S.A. Process for obtaining enantiomers of duloxetine precursors
US20080015362A1 (en) * 2006-04-17 2008-01-17 Santiago Ini Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine
PT1857451E (pt) * 2006-05-05 2010-10-25 Fidia Farmaceutici Processo para a preparação de uma substância intermédia útil para a síntese assimétrica da (+)duloxetina
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
ITMI20060984A1 (it) * 2006-05-18 2007-11-19 Dipharma Spa Procedimento per la preparazione di arilossipropilammine
CN101448815A (zh) * 2006-05-23 2009-06-03 特瓦制药工业有限公司 度洛西汀hci多晶型物
WO2007143065A2 (en) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. Process for preparing duloxetine and intermediates thereof
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612506D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
CN101484435A (zh) * 2006-07-03 2009-07-15 兰贝克赛实验室有限公司 制备n-甲基-3-（1-萘氧基）-3-（2-噻吩基）丙胺及其纯对应异构体盐的方法
CN101522189A (zh) * 2006-07-03 2009-09-02 兰贝克赛实验室有限公司 盐酸度洛西汀的多晶型
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
EP2114912B1 (en) * 2006-12-22 2012-04-04 Synthon B.V. Process for making duloxetine and related compounds
WO2008081476A2 (en) * 2006-12-29 2008-07-10 Cadila Healthcare Limited Process for preparing duloxetine hydrochloride
WO2008093360A2 (en) * 2007-01-31 2008-08-07 Usv Limited A process for preparation of (s)-(+)-n-methyl-3(1-naphthyloxy)-3(2-thienyl)propylamine hydrochloride
EP2132192B1 (en) * 2007-03-05 2013-04-24 Lupin Limited Novel process for preparation of duloxetine hydrochloride
KR20100028559A (ko) * 2007-05-18 2010-03-12 시플라 리미티드 데스메틸시탈로프람을 경유한 에스시탈로프람의 제조방법, 상기 ｓ-이성체의 광학분리 및 메틸화
CL2008002032A1 (es) * 2007-07-13 2009-01-23 Synthon Bv Forma de dosis farmaceutica que posee una pluralidad de pellets, cada pellet comprende, un nucleo de pellet con un diametro de 600 a 1000 micrometros, capa de farmaco que comprende duloxetina o una sal y aglutinante de preferencia metil celulosa, una capa de separacion y una capa de recubrimiento enterico; proceso de preparacion
EP2060559A1 (en) 2007-11-19 2009-05-20 Cadila Pharmaceuticals Limited Process for the preparation of enantiomerically pure 3-hydroxy-3-arylpropylamines and their optical stereoisomers
US20100267968A1 (en) * 2007-12-26 2010-10-21 Orchid Chemicals & Pharmaceuticals Limited Method for the preparation of duloxetine hydrochloride
EP2240173A4 (en) 2008-01-25 2013-07-17 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION OF DULOXETINE WITH DELAYED RELEASE
EP2107057A1 (en) 2008-04-04 2009-10-07 Ranbaxy Laboratories Limited Process for the preparation of pure duloxetine hydrochloride
CN101998866A (zh) * 2008-04-11 2011-03-30 尼克塔治疗公司 低聚物-芳氧基-取代的丙胺共轭物
WO2009130708A2 (en) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Preparation of duloxetine and its salts
WO2009147687A2 (en) * 2008-06-03 2009-12-10 Shodhana Laboratories Limited An improved process for the separation of enantiomerically pure compounds
EP2133072A1 (en) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
US8288141B2 (en) * 2008-08-27 2012-10-16 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2010025238A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
CA2758736A1 (en) * 2009-01-06 2010-07-15 Alembic Pharmaceuticals Limited An improved process for the reparation of duloxetine and salts thereof
WO2010103443A1 (en) * 2009-03-13 2010-09-16 Alembic Limited A process for the preparation of duloxetine hydrochloride
CZ304602B6 (cs) 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
WO2011033366A2 (en) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Process for the preparation of duloxetine hydrochloride and its precursors
WO2011077443A1 (en) * 2009-12-22 2011-06-30 Biocon Limited An improved process for the preparation of duloxetine hydrochloride
SI2558455T1 (sl) * 2010-04-13 2017-12-29 Krka, D.D., Novo Mesto Sinteza duloksetina in/ali njegovih farmacevtsko sprejemljivih soli
US20130053579A1 (en) 2010-05-18 2013-02-28 Arch Pharmalabs Limited Process for the preparation of n-methyl-o-aryloxy propanamine derivatives and pharmaceutically acceptable salt thereof
US11011709B2 (en) 2016-10-07 2021-05-18 Universal Display Corporation Organic electroluminescent materials and devices
AU2018445164A1 (en) 2018-10-11 2021-04-22 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
CN114163415B (zh) * 2021-12-01 2023-03-03 珠海润都制药股份有限公司 一种盐酸度洛西汀中间体的制备方法
CN115286613B (zh) * 2022-10-08 2023-01-31 潍坊市海欣药业有限公司 一种盐酸度洛西汀的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558164A (en) * 1984-08-06 1985-12-10 E. I. Du Pont De Nemours And Company Production of dinitrodiphenyl ether
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
FI81083C (fi) * 1989-03-03 1990-09-10 Orion Yhtymae Oy Ett foerbaettrat foerfarande foer framstaellning av n-metyl-3-(p-trifluormetylfenoxi)-3-fenylpropylamin hydroklorid.
JP2707148B2 (ja) * 1990-04-20 1998-01-28 チッソ株式会社 光学活性フルオキセチンの製造方法とこの方法に使用する化合物
US5068451A (en) * 1990-05-04 1991-11-26 National Science Council Production of 3-phenoxy propanal derivatives
CA2042346A1 (en) * 1990-05-17 1991-11-18 Michael Alexander Staszak Chiral synthesis of 1-aryl-3-aminopropan-1-ols
CA2053997A1 (en) * 1991-03-15 1992-09-16 Jeffrey S. Stults Method for ether formation
DE4123253A1 (de) * 1991-07-15 1993-01-21 Schneider Manfred Prof Dr Verfahren zur enzymatischen racematspaltung halogenierter arylalkanole
HU9202128D0 (en) * 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine

Also Published As

Publication number Publication date
CA2133899C (en) 2007-02-13
JPH07188065A (ja) 1995-07-25
MY112254A (en) 2001-05-31
PE18595A1 (es) 1995-07-13
PL179600B1 (pl) 2000-09-29
NO943825D0 (no) 1994-10-10
TW381090B (en) 2000-02-01
CZ246594A3 (en) 1995-05-17
IL111188A0 (en) 1994-12-29
HUT68943A (en) 1995-08-28
EP0650965B1 (en) 2001-02-07
HU68943D0 (en) 2000-04-28
BR9404045A (pt) 1995-06-13
IL111188A (en) 1998-06-15
DE69426663T2 (de) 2001-06-21
PT650965E (pt) 2001-05-31
CA2133899A1 (en) 1995-04-13
NZ264633A (en) 1997-09-22
FI944773A0 (fi) 1994-10-11
JP3644986B2 (ja) 2005-05-11
SI0650965T1 (en) 2001-06-30
CN1109470A (zh) 1995-10-04
YU49027B (sh) 2003-07-07
CZ286122B6 (cs) 2000-01-12
EP0650965A1 (en) 1995-05-03
RU2127269C1 (ru) 1999-03-10
AU7572094A (en) 1995-05-04
NO943825L (no) 1995-04-18
AU685494B2 (en) 1998-01-22
NO301758B1 (no) 1997-12-08
HU220673B1 (hu) 2002-04-29
ES2153850T3 (es) 2001-03-16
YU59194A (sh) 1997-03-07
RU94035996A (ru) 1996-08-20
KR950011434A (ko) 1995-05-15
CN1067681C (zh) 2001-06-27
US5362886A (en) 1994-11-08
PH31595A (en) 1998-11-03
DE69426663D1 (de) 2001-03-15
KR100334585B1 (ko) 2005-07-28
FI944773A (fi) 1995-04-13
HU9402936D0 (en) 1995-01-30
PL305326A1 (en) 1995-04-18
GR3035715T3 (en) 2001-07-31
ZA947839B (en) 1996-04-09
CO4290349A1 (es) 1996-04-17
US5491243A (en) 1996-02-13
ATE199084T1 (de) 2001-02-15

Similar Documents

Publication Publication Date Title
DK0650965T3 (da) Asymmetrisk syntese af (S)-(+)-N,N-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamin, et mellemprodukt ved fremstilling
ES539658A0 (es) Procedimiento de preparacion de nuevos derivados de la xan- tina y de sus sales de adicion con acidos apropiados
BR0207294A (pt) Composto, processo para a preparação de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável ou um éster hidrolisável in vivo dos mesmos, e, método para a produção de um efeito inibitório do ciclo celular (antiproliferação celular) em um animal de sangue quente
SE8302464D0 (sv) Aromatiskt alkanderivat samt sett for framstellning derav
ATE380804T1 (de) Verfahren zur herstellung von (s)-n-methyl-3-(1- naphthyloxy)-3-(2-thienyl)propylaminhydrochlori (duloxetin)
ES499870A0 (es) Un procedimiento para la preparacion de derivados de indano
DE68929277D1 (de) Verfahren zur Herstellung von Purinderivaten
AU1400801A (en) Aralkyl-1,2-diamines having calcimimetic activity and preparation mode
IE830142L (en) 2-(phenoxyalkyl)-imidazoles
IE792281L (en) Antithrombic composition
KR910011815A (ko) 티아졸릴-5-카본아미드 유도체 및 그의 제조방법
PT90614A (pt) Processo para a preparacao de tienil-piperazinonas e de composicoes farmaceuticas que os contem
TH16646A (th) การสังเคาะห์แบบอสมมาตร
ATE12390T1 (de) Basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung.
GB1518722A (en) Pharmaceutical composition containing cephalosporin compounds
KR970061861A (ko) 오르토 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이 용도 및 이를 함유하는 약제
DE3168174D1 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
KR870007915A (ko) N-헤테로사이클릴-4-피페리딘아민 유도체의 제조방법